Introduction
Doxorubicin (DOX) is an anthracycline antibiotic with a broad spectrum of activity and high potency against human malignant neoplasms. However, its clinical use is limited by its severe cumulative doserelated cardiotoxicity (1) . It has been suggested that one of the molecular mechanisms responsible for DOX cardiotoxicity is the formation of reactive oxygen species (ROS) (2) . The quinone moiety of DOX undergoes a one-electron reduction that is catalyzed by NAD(P)H reductases to yield a semiquinone free-radical intermediate, which regenerates the parent quinone by reacting with O 2 to form O 2 − and H 2 O 2 (3, 4) . These ROS can then be transformed into the more potent hydroxyl radical HO• which is capable of damaging DNA and proteins, and initiating membrane lipid peroxidation, thus eventually leading to intracellular calcium overload (5) , cell death, and cardiac damage. Oxidative stress is now considered a major contributor as a trigger for cardiomyocyte death by apoptosis or cell necrosis (1, 6, 7) . Treatment with antioxidants or natural phenolic compounds has been found to protect against DOX-induced cardiotoxicity (8) .
The Chinese traditional medicine Dracocephalum rupestre Hance, a wild perennial herb found throughout western China, contains a high content of flavonoids (9) , and has offered therapeutic potential for Original Article cardiovascular diseases. In our continuous search for cardioprotective substances from these natural products (10) (11) (12) , naringenin-7-O-glucoside (NARG), a major active flavonoid isolated from D. rupestre, has been demonstrated that NARG was able to up-regulate the expression of heme oxygenase-1 (HO-1) and attenuate DOX-induced H9c2 cell apoptosis (13) . NARG could prevent cardiomyocytes from DOX-induced toxicity by induction of endogenous antioxidant enzymes via phosphorylation of ERK1/2 and nuclear translocation of Nrf2 (14) . In the present study, we investigated the effects of NARG on cell membrane stability and ROS generation in H9c2 cardiomyocytes treated with DOX. These results suggest that NARG could prevent cardiomyocytes from DOX-induced injury by their property of stabilizing the cell membrane and reducing ROS generation.
Materials and Methods

Chemicals and materials
NARG was isolated from D. rupestre in our laboratory (15, 16) and dissolved in dimethyl sulfoxide (DMSO) for the in vitro bioassay. Dulbecco's modified Eagle's medium (DMEM) was purchased from Gibco BRL (Grand Island, NY, USA). Fetal bovine serum was bought from Tianjin TBD Biotechnology Development Center (Tianjin, China). 3-[4,5-Dimethyl-2-thiazolyl]-2,5-diphenyl-2-tetrazolium bromide (MTT) were purchased from Sigma. Lactate dehydrogenase (LDH), glutathione peroxidase (GSH-Px) and creatine kinase (CK) assay kits were from Nanjing Jiancheng Bioengineering Institute (Nanjing, China); the ROS assay kit was from Applygen Technologies Inc. (Beijing, China). Fura-2/AM Ester was provided by Biotium (Hayward, CA, USA).
Cell culture
Rat cardiac H9c2 cells (ATCC Rockville, MD, USA) were cultured in DMEM supplemented with 10% fetal bovine serum, 100 U/mL of penicillin, 100 μg/ mL of streptomycin and 5% CO 2 at 37°C. The cells were fed every 2-3 days and subcultured once they reached 70-80% confluence. Cells were plated at an appropriate density according to each experimental design.
Cell treatment with NARG
H9c2 cells were incubated with NARG for 24 h followed by incubation with DOX (10 μM) for another 24 h. After this incubation, cells were harvested after trypsin digestion by centrifugation (1 000 rpm × 5 min) and parameters were measured as described in materials and methods.
In vitro cell proliferation
H9c2 cells were seeded in 96-well plates at a density of 5,000 cells/well. Following overnight adherence, cells were incubated with NARG (5, 10, 20, 40, and 80 μM) in DMEM supplemented with 0.5% fetal bovine serum at 37°C for 24 h followed by incubation with/without DOX (10 μM) for another 24 h, and then cell proliferation was determined by MTT assay. Cells were treated with MTT solution (final concentration, 0.5 mg/mL) for 4 h. The supernatants were removed carefully, followed by addition of 100 μL DMSO to each well to dissolve the precipitate. The absorbance was measured at 570 nm in a microplate reader (Synergy HT).
Analysis for generation of ROS
The production of ROS was measured by detecting the fluorescent intensity of an oxidant-sensitive probe CM-H2DCFDA, which is a stable nonfluorescent molecule that passively diffuses into cells, where the acetate can be cleaved by intracellular esterases to produce a polar diol that is well retained within the cells. H9c2 cells were seeded at a density of 1 × 10 4 cells/well in a 96-well plate and 1 × 10 6 cells/well in a 6-well plate. The next day, cells were pretreated with/without NARG (5, 10, and 20 μM) for 24 h followed by incubation with DOX (10 μM) for another 24 h. Then cells were loaded with CM-H2DCFDA (10 μM) as per the manufacturer's protocol for 3 h. Fluorescent intensity was recorded by excitation at 485 nm and emission at 535 nm using a Wallac 1420 Multilabel Counter (Wallac, Turku, Finland). Cells in the 6-well plate were observed under a fluorescence microscope (IX-7, Olympus, Tokyo, Japan) (×200).
Cell morphological analysis
H9c2 cells were seeded at a density of 1 × 10 6 cells/well in a 6-well plate, and the cells were grown overnight at 37°C in a humidified incubator with 5% CO 2 . The next day, cells were pretreated with/without NARG (10 and 20 μM) for 24 h, and then exposed to DOX (10 μM) for another 24 h. After this incubation, cell morphology was examined without/with Wright's Giemsa staining under an inversion microscope (×200).
Measurement of excellular LDH content, CK levels and cellular GSH-Px activity
H9c2 cells were treated with NARG for 24 h, followed by incubation with 10 μM DOX for another 24 h. After collecting cell culture supernatants extracellular LDH content and CK levels were measured using commercially available colorimetric assay kits respectively. Treated cells were harvested and resuspended in cell lysis buffer (13), supernatants and 80 μM) in the absence of DOX for 24 h and then the rates of cell growth inhibition were evaluated. As shown in Figure 1A , NARG at each of these concentrations alone did not cause any apparent cytotoxicity. To analyze the effects of NARG on DOXinduced cytotoxicity in H9c2 cells, cell proliferation was examined after incubation with NARG in the presence of DOX (10 μM). As shown in Figure 1B , NARG (5, 10, 20, 40 , and 80 μM) pretreatment provided significant protective effects on DOXmediated cytotoxicity in a dose-dependent manner at low doses.
To determine whether NARG could protect H9c2 cells from DOX-induced injury, cell morphology was examined without/with Wright's Giemsa staining under an inverted microscope. As shown in Figure 2A , normal cells were seen as spindle-shaped with integral and clear structures (Aa). NARG (10 and 20 μM) alone had no apparent effects on H9c2 cells (Ab and Ac). Treatment with DOX (10 μM) for 24 h leads to alterations in cell shape, which include cell shrinkage starting from the periphery and accompanied by membrane blebbing. DOX also induced rapid changes in the nuclear morphology of H9c2 cells with increased nucleus size and chromatin condensation (Ad). Pretreatment with 10 and 20 μM NARG significantly protected the cells from the morphological changes induced by DOX as shown in Figure 2A (Ae and Af). This result is consistent with the morphological analysis using Wright's Giemsa separated were used for measurement of GSH-Px activity according to the commercially available colorimetric assay kits. indicator Fura-2/AM using the Multilabel Counter Victor-1420. Briefly, H9c2 cells were seeded at a density of 1 × 10 6 cells/well in a 6-well plate, and the cells were grown overnight at 37°C in a humidified incubator with 5% CO 2 . The next day, cells were pretreated with/without NARG (5, 10 and 20 μM) for 24 h, and exposed to DOX (10 μM) for another 24 h. After this incubation, cells were resuspended in Hanks' solution at a density of 10 6 -10 7 cells/mL. Trypan blue staining showed a 90%-95% cellular viability rate. A final concentration of 5 μM Fura-2/AM was added to the above isolated cell suspensions incubated at 37°C for 35 min, and then were washed with Hank's solution containing 0.1% bovine serum albumin to wash out the residual Fura-2/AM. The cells were resuspended in Hank's solution and incubated for five minutes at 37°C prior to measurements. The basal emission was measured by stimulating the cells with 340 to 380 nm light and recording the emitted fluorescence intensity at 510 nm. In order to calculate [Ca 2+ ]i, calibration at high and low [Ca 2+ ]i was made after the cells were treated with 0.1% Triton X-100 in PBS, followed by exchanging with calcium-free medium containing 5 mM EGTA in PBS. This produced calcium signals equivalent to saturated calcium and to zero calcium. Calculation of intracellular calcium was made using the following equation (17, 18) 2+ and is assumed to be 224 nM at 37°C . R is the ratio of corrected fluorescence at 340 and 380 nm. Rmax is the ratio obtained after 0.1% Triton X-100 treatment. Rmin is the ratio obtained after EGTA treatment. Fmin and Fmax are fluorescent intensity at 380 nm after EGTA and 0.1% Triton X-100 treatment respectively.
Statistical analysis
All data are expressed as mean ± S.D. from at least four independent experiments. Differences between mean values of multiple groups were analyzed by Student's t-test. Statistical significance was considered at p < 0.05.
Results
NARG protects H9c2 cells from DOX-induced cytotoxicity
H9c2 cells were treated with NARG (5, 10, 20, 40, ## p < 0.01 compared to the normal group; * p < 0.05 , ** p < 0.01 compared to DOX group. staining ( Figure 2B ).
Determination of cellular ROS
One potential mechanism for DOX-induced cell damage seems to be linked to an increased production of ROS (2, 19) . Oxidative stress precedes the development of irreversible cell injury after DOX exposure in H9c2 cells. To determine whether pretreatment with NARG mitigated DOX-induced early oxidative stress, cellular ROS contents were measured by incubating the control or drug-treated cells with 10 μM CM-H2DCFDA. As shown in Figures 3A and 3B , exposure to DOX without NARG significantly increased fluorescence, indicating that DOX generated oxidative stress. Pretreatment with NARG (5, 10, and 20 μM) significantly inhibited the elevated intracellular concentration of ROS compared with DOX treated cells.
Measurement of excellular LDH content and CK levels and GSH-Px activity
The integrity of plasma membranes was determined by monitoring the activity of cytoplasmic enzyme LDH and CK in the extracellular incubation medium, which represents a common procedure to determine membrane leakage and cellular damage. As shown in Table 1 , compared with normal cells, exposure to DOX without NARG, the released amount of LDH and CK was increased for both; the activity of GSH-Px was decreased. Compared with DOX, NARG significantly decreased the amount of released LDH and the content of CK, but the activity of GSH-Px was increased; these results suggest that NARG could prevent cardiomyocytes from DOX-induced toxicity partly by their property of stabilizing cell membranes.
The measurement of the intracellular Ca
2+
concentration DOX-mediated alteration of Ca 2+ homeostasis is another possible mechanism of cardiotoxicity. Intracellular Ca 2+ accumulation is thought to initiate myocardial injury and contractile impairment. In the present study, intracellular Ca 2+ levels were determined using the intracellular Ca 2+ probe Fura-2/AM. As depicted in Figure 4 , [Ca 2+ ]i level was quite low in normal cells. Cardiomyocytes exposed to DOX without NARG had ]i rise in a dose-dependent manner.
Discussion
DOX is a widely used chemotherapeutic agent for treatment of various cancers. However, its clinical use is limited by its severe cumulative dose-related cardiotoxicity (20, 21) . Although DOX-induced injury appears to be multifactorial, one of the possible mechanisms is cellular damage mediated by generation of ROS (22) . DOX-induced cardiotoxicity is associated with the accumulation of DOX in the mitochondria and ROS production (19, 23) . The heart is especially susceptible to oxidative damage because cardiomyocytes are rich in mitochondria, the site of basal ROS generation, and are exposed to relatively high oxygen tension compared to other tissues. In normal healthy cells, endogenous antioxidants, such as manganese superoxide dismutase (MnSOD), are able to detoxify basal ROS generation in mitochondria. However, as DOX accumulates and generates ROS, the system becomes easily overwhelmed, and thus, oxidative damage occurs. Therefore, an effective cardioprotective agent perhaps acts partly by preventing DOX-induced ROS production.
Furthermore, ROS may lead to cardiomyocyte apoptosis, endogenous antioxidant system destruction and Ca 2+ overload. Ca 2+ overload can further increase ROS synthesis and is considered an initiating agent of cell apoptosis. Therefore, protection or alleviation of DOX cardiotoxicity can be achieved by reducing oxidative damage, decreasing Ca 2+ overload, and activating endogenous defense systems.
Due to the successful action of DOX as a chemotherapic agent, several strategies have been tried to prevent/attenuate the side effects of DOX. Treatment with antioxidants or natural phenolic compounds such as flavonoids has been found to protect against DOXinduced cardiotoxicity via radical-scavenging (24), iron-chelating (25) , activating endogenous defense systems (26, 27) and regulating intracellular Ca 2+ homeostasis (5) .
It has been demonstrated that NARG, a major active flavonoid isolated from D. rupestre Hance, did not cause apparent cytotoxicity at each investigated low dose alone and could prevent H9c2 cardiomyocytes f r o m D O X -i n d u c e d t o x i c i t y b y i n d u c t i o n o f endogenous antioxidant enzymes via phosphorylation of extracellular signal-regulated kinase1/2 (Erk1/2) and nuclear translocation of nuclear factor E2 P45-related factor 2 (Nrf2) (13) . NARG could protect against cardiomyocyte apoptosis by modulation of apoptosisrelated genes (Bcl-2, caspase-3, and caspase-9) and HO-1 expression (14) . Pretreatment with NARG could elevate not only the activities of SOD and catalase (CAT) but also phase 2 metabolizing enzymes such as HO-1 and NAD(P)H: quinine oxidoreductase 1 (NQO1). NARG also could decrease the level of malonaldehyde (MDA) and increase the intracellular reduced glutathione (GSH) level by up-regulating the expression of glutamate-cysteine ligase modifier subunit (GCLM) and glutamate-cysteine ligase catalytic subunit (GCLC) mRNA (13) . In this study, we found that pretreatment with NARG increased the activity of GSH-Px.
Efficient detoxification of ROS requires the coordinated actions of various cellular antioxidant enzymes. Accordingly, simultaneous induction of key cellular antioxidant enzymes by NARG in cardiomyocytes appears to be a promising strategy for protecting against oxidative injury and may be an important mechanism underlying the protective effects of NARG observed in DOX-induced cardiotoxicity. Although the direct antioxidant effects of NARG were not studied. In the present study, we found that compared with DOX, the morphological injury of cells treated with NARG was alleviated, cell viability was increased; the amount of released LDH and CK was significantly decreased; and the content of intracellular Ca 2+ and ROS generation was lowered remarkably. These results suggest that NARG could prevent cardiomyocytes from DOX-induced toxicity by its property of stabilizing cell membranes and reducing ROS generation.
In conclusion, the protection by NARG against DOX-induced oxidative damage and cardiomyocyte death occurs through inhibition of cell death, increased antioxidant activity, decreased cellular calcium overload, and increased mitochondrial function. The findings in our paper of NARG protection against DOX-induced cardiotoxicity conclude that in H9c2 cardiomyocytes NARG is able to prevent DOXinduced oxidative damage and cell death, which is very promising; however, whole animal studies are necessary as the next step to evaluate the ability of NARG to protect the heart from DOX in vivo.
